Research Progress in Cyclopeptide: Anticancer Mechanisms and Targeted Delivery Systems

Jie Tang
DOI: https://doi.org/10.54097/hbm13q78
2024-01-01
Abstract:Breast cancer is a serious health concern for women globally. Traditional therapies including surgery chemotherapy, radiotherapy and endocrine therapy can control breast cancer effectively, but their effectiveness is often hindered by drug resistance and side effects. Cyclopeptides, a class of biomolecules with a closed-loop structure, present a promising alternative due to their stability potency and specificity.This review delves into the mechanisms of cyclopeptides in breast cancer treatment, evaluating their effectiveness and challenges. And also discusses the studies concerning the anti-cancer activities and delivery systems of cyclopeptides such as cyclosporin A and deoxybouvardin (RA-V). Innovations in nanotechnology and targeted delivery systems further optimize cyclopeptide therapies, enhancing their efficiency and reducing side effects. Research suggests that cyclopeptides can effectively halt the proliferation and metastasis of breast cancer cells. They achieve this through various mechanisms, such as inhibiting key cancer pathways, inducing tumor cell apoptosis, and enhancing drug efficacy via targeted delivery systems. This review highlights the application of cyclopeptides in breast cancer treatment and discusses the targeted delivery technologies of cyclopeptides.
What problem does this paper attempt to address?